BURNABY, BC, Canada, October 1, 2007 – Twinstrand Therapeutics Inc. today announced that an abstract entitled, “Phase I study of the ribosome inactivating protein prodrug TST10088 (TST88) in patients with advanced solid tumors”, has been accepted for presentation at the Molecular Targets and Cancer Therapeutics International Conference to be held in San Francisco, California on October 22-26, 2007. A poster presentation of clinical data (abstract number B149) will be given on October 24, 2007 by clinical investigators Ignacio Duran and Lillian Siu, from the Princess Margaret Hospital (Toronto, ON) and Lia Gore, S. Gail Eckhardt and Stephen Leong from the University of Colorado Cancer Center (Aurora, CO).
